Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 191

1.

Effects of miglitol in combination with intensive insulin therapy on blood glucose control with special reference to incretin responses in type 1 diabetes mellitus.

Nagai E, Katsuno T, Miyagawa J, Konishi K, Miuchi M, Ochi F, Kusunoki Y, Tokuda M, Murai K, Hamaguchi T, Namba M.

Endocr J. 2011;58(10):869-77. Epub 2011 Aug 26.

2.
3.

Effects of miglitol, sitagliptin or their combination on plasma glucose, insulin and incretin levels in non-diabetic men.

Aoki K, Masuda K, Miyazaki T, Togashi Y, Terauchi Y.

Endocr J. 2010;57(8):667-72. Epub 2010 Jun 1. Erratum in: Endocr J. 2010;57(12):1089.

4.

Cotreatment with the α-glucosidase inhibitor miglitol and DPP-4 inhibitor sitagliptin improves glycemic control and reduces the expressions of CVD risk factors in type 2 diabetic Japanese patients.

Imai C, Saito M, Mochizuki K, Fuchigami M, Goda T, Osonoi T.

Metabolism. 2014 Jun;63(6):746-53. doi: 10.1016/j.metabol.2013.12.014. Epub 2014 Jan 7.

PMID:
24559582
5.
6.

Teneligliptin improves glycemic control with the reduction of postprandial insulin requirement in Japanese diabetic patients.

Tsuchimochi W, Ueno H, Yamashita E, Tsubouchi C, Sakoda H, Nakamura S, Nakazato M.

Endocr J. 2015;62(1):13-20. doi: 10.1507/endocrj.EJ14-0393. Epub 2014 Sep 25.

7.
8.

Miglitol administered before breakfast increased plasma active glucagon-like peptide-1 (GLP-1) levels after lunch in patients with type 2 diabetes treated with sitagliptin.

Aoki K, Kamiyama H, Yoshimura K, Shibuya M, Masuda K, Terauchi Y.

Acta Diabetol. 2012 Jun;49(3):225-30. doi: 10.1007/s00592-011-0322-9. Epub 2011 Sep 6. Erratum in: Acta Diabetol. 2012 Jun;49(3):231.

PMID:
21898126
9.

Comparisons of the effects of 12-week administration of miglitol and voglibose on the responses of plasma incretins after a mixed meal in Japanese type 2 diabetic patients.

Narita T, Yokoyama H, Yamashita R, Sato T, Hosoba M, Morii T, Fujita H, Tsukiyama K, Yamada Y.

Diabetes Obes Metab. 2012 Mar;14(3):283-7. doi: 10.1111/j.1463-1326.2011.01526.x. Epub 2011 Dec 2.

PMID:
22051162
10.

The effects of miglitol on glucagon-like peptide-1 secretion and appetite sensations in obese type 2 diabetics.

Lee A, Patrick P, Wishart J, Horowitz M, Morley JE.

Diabetes Obes Metab. 2002 Sep;4(5):329-35.

PMID:
12190996
11.

Effect of miglitol as an add-on to bolus insulin on postprandial glycemic excursions in type 2 diabetes patients assessed by continuous glucose monitoring.

Matsuura K, Mori Y, Nakamura A, Yokoyama J, Utsunomiya K.

Diabetes Technol Ther. 2012 May;14(5):423-9. doi: 10.1089/dia.2011.0188. Epub 2012 Feb 8.

PMID:
22316114
12.

Addition of sitagliptin or metformin to insulin monotherapy improves blood glucose control via different effects on insulin and glucagon secretion in hyperglycemic Japanese patients with type 2 diabetes.

Otsuka Y, Yamaguchi S, Furukawa A, Kosuda M, Nakazaki M, Ishihara H.

Endocr J. 2015;62(2):133-43. doi: 10.1507/endocrj.EJ14-0148. Epub 2014 Oct 19.

13.
14.

Glucose-dependent insulinotropic polypeptide augments glucagon responses to hypoglycemia in type 1 diabetes.

Christensen M, Calanna S, Sparre-Ulrich AH, Kristensen PL, Rosenkilde MM, Faber J, Purrello F, van Hall G, Holst JJ, Vilsbøll T, Knop FK.

Diabetes. 2015 Jan;64(1):72-8. doi: 10.2337/db14-0440. Epub 2014 Jul 22.

15.

Effects of miglitol, sitagliptin, and initial combination therapy with both on plasma incretin responses to a mixed meal and visceral fat in over-weight Japanese patients with type 2 diabetes. "the MASTER randomized, controlled trial".

Mikada A, Narita T, Yokoyama H, Yamashita R, Horikawa Y, Tsukiyama K, Yamada Y.

Diabetes Res Clin Pract. 2014 Dec;106(3):538-47. doi: 10.1016/j.diabres.2014.09.040. Epub 2014 Oct 7.

PMID:
25451890
16.

The effect of liraglutide added to U-500 insulin in patients with type 2 diabetes and high insulin requirements.

Lane W, Weinrib S, Rappaport J.

Diabetes Technol Ther. 2011 May;13(5):592-5. doi: 10.1089/dia.2010.0221. Epub 2011 Mar 15.

PMID:
21406014
17.

Concomitant use of miglitol and mitiglinide as initial combination therapy in type 2 diabetes mellitus.

Tatsumi F, Hashiramoto M, Hirukawa H, Kimura T, Shimoda M, Tawaramoto K, Kanda-Kimura Y, Anno T, Kawasaki F, Mune T, Matsuki M, Kaku K.

Diabetes Res Clin Pract. 2013 Jul;101(1):35-44. doi: 10.1016/j.diabres.2013.04.007. Epub 2013 May 24.

PMID:
23711593
18.

Effects of short-term therapy with glibenclamide and repaglinide on incretin hormones and oxidative damage associated with postprandial hyperglycaemia in people with type 2 diabetes mellitus.

Stephens JW, Bodvarsdottir TB, Wareham K, Prior SL, Bracken RM, Lowe GD, Rumley A, Dunseath G, Luzio S, Deacon CF, Holst JJ, Bain SC.

Diabetes Res Clin Pract. 2011 Nov;94(2):199-206. doi: 10.1016/j.diabres.2011.07.014. Epub 2011 Aug 10.

PMID:
21835486
19.

Restoration of the insulinotropic effect of glucose-dependent insulinotropic polypeptide contributes to the antidiabetic effect of dipeptidyl peptidase-4 inhibitors.

Aaboe K, Akram S, Deacon CF, Holst JJ, Madsbad S, Krarup T.

Diabetes Obes Metab. 2015 Jan;17(1):74-81. doi: 10.1111/dom.12395. Epub 2014 Oct 26.

PMID:
25243647
20.

Efficacy of combined use of miglitol in Type 2 diabetes patients receiving insulin therapy-placebo-controlled double-blind comparative study.

Nemoto M, Tajima N, Kawamori R.

Acta Diabetol. 2011 Mar;48(1):15-20. doi: 10.1007/s00592-010-0206-4. Epub 2010 Jul 9.

PMID:
20617348

Supplemental Content

Support Center